Apellis Pharmaceuticals (NASDAQ:APLS) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS - Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $92.00 target price on the stock.

Several other equities research analysts have also recently issued reports on APLS. The Goldman Sachs Group raised their price target on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a buy rating in a research note on Tuesday, January 9th. JPMorgan Chase & Co. lifted their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an overweight rating in a research note on Wednesday, March 6th. Oppenheimer boosted their price target on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an outperform rating in a report on Tuesday, January 30th. Jefferies Financial Group upgraded Apellis Pharmaceuticals from a hold rating to a buy rating and raised their price objective for the stock from $68.00 to $80.00 in a report on Monday, February 5th. Finally, Mizuho reiterated a neutral rating and issued a $60.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, March 27th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $78.60.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock traded down $0.29 during mid-day trading on Monday, reaching $51.50. The company had a trading volume of 2,616,448 shares, compared to its average volume of 1,502,664. The stock's 50-day simple moving average is $61.22 and its 200-day simple moving average is $57.00. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. The company has a market capitalization of $6.21 billion, a P/E ratio of -11.50 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting the consensus estimate of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. Apellis Pharmaceuticals's quarterly revenue was up 545.9% on a year-over-year basis. During the same period last year, the business posted ($1.50) EPS. On average, equities analysts predict that Apellis Pharmaceuticals will post -1.33 EPS for the current year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, CAO James George Chopas sold 864 shares of the firm's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $66.81, for a total value of $57,723.84. Following the transaction, the chief accounting officer now owns 40,128 shares of the company's stock, valued at approximately $2,680,951.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Jeffrey Eisele sold 438 shares of the business's stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total transaction of $29,262.78. Following the transaction, the insider now directly owns 72,650 shares of the company's stock, valued at approximately $4,853,746.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO James George Chopas sold 864 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $66.81, for a total transaction of $57,723.84. Following the completion of the sale, the chief accounting officer now directly owns 40,128 shares of the company's stock, valued at approximately $2,680,951.68. The disclosure for this sale can be found here. Insiders have sold a total of 422,279 shares of company stock valued at $26,174,364 over the last ninety days. Corporate insiders own 7.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Apellis Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company's stock worth $572,003,000 after buying an additional 85,701 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Apellis Pharmaceuticals by 1.0% in the first quarter. BlackRock Inc. now owns 5,923,920 shares of the company's stock worth $300,993,000 after acquiring an additional 58,208 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Apellis Pharmaceuticals by 5.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,842,660 shares of the company's stock valued at $302,124,000 after purchasing an additional 326,537 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Apellis Pharmaceuticals by 66.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,590,040 shares of the company's stock valued at $302,760,000 after purchasing an additional 1,840,498 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in Apellis Pharmaceuticals by 79.8% during the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company's stock valued at $134,746,000 after purchasing an additional 1,571,606 shares in the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).